We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Jonathan Routh

Jonathan C. Routh MD, MPH, FAAP

Paul H. Sherman Endowed Associate Professor of Surgery, Pediatrics, and Population Health Sciences, Division of Urology, Duke University School of Medicine, Durham, North Carolina

Dr. Jonathan C. Routh is a pediatric urologist and health services researcher at Duke University School of Medicine, where he serves as the Paul H. Sherman Endowed Associate Professor of Surgery, Pediatrics, and Population Health Sciences.  Dr. Routh’s clinical interests include minimally-invasive surgery, complex urologic reconstruction (particularly among individuals with spina bifida), surgical and non-surgical management of children with disorders of sex development, and pediatric urologic oncology (particularly rhabdomyosarcoma and Wilms’ tumor).  He is the Surgical Director of the Duke Child and Adolescent Gender Program and is a member of the US News and World Report Best Children's Hospitals Rankings Working Group for Urology.

Dr. Routh is an accomplished health services researcher, having published more than 150 peer-reviewed research articles.  He is the Chair of the Steering Committee for the multi-institutional, CDC-funded Urologic Management to Preserve Initial Renal Function Protocol for Young Children with Spina Bifida (UMPIRE) study; co-PI for the Duke University National Spina Bifida Patient Registry; President of the Society for Pediatric Urology Oncology Working Group; a member of the Children’s Oncology Group (COG) Surgery, Soft Tissue Sarcoma, and ARST1431 Intermediate Risk Rhabdomyosarcoma study committees; a member of the Urinary Tract and Endocrine Task Forces of the COG Long-Term Follow-up Committee; and a member of the Paratesticular and Bladder/Prostate Working Groups of the International Soft Tissue Sarcoma Consortium.

Disclosures

Dr. Routh has no relevant disclosures.